Navigation Links
Kymab Announces Launch of Kymouse HK
Date:9/18/2012

CAMBRIDGE, England, September 18, 2012 /PRNewswire/ --

First human antibody strain from its advanced discovery platform

Kymab, a monoclonal antibody biopharmaceutical company, announced today the launch of Kymouse HK, the first strain from the innovative Kymouse™ antibody discovery platform, which enables rapid discovery of high affinity antibody drug candidates.

Kymouse HK is a transgenic mouse that has been designed to produce a diverse repertoire of high affinity fully human heavy/kappa chain antibodies to a broad range of drug targets. This represents a significant advance over existing commercial strains that are currently used in the pharmaceutical industry.

Kymouse is an antibody discovery platform that has been designed to surpass the diversity of antibodies produced in humans. The platform provides unique tools to discover functional and developable drug candidates to address challenging drug targets. The platform is covered by a strong intellectual property portfolio, including a European Patent (EP2421357) that has received notice of allowance from the European Patent Office.

Dr. Allan Bradley, Chief Scientific Officer of Kymab, said: "Our Kymouse HK strain involves targeted insertion of human heavy chain and kappa chain genes into the corresponding mouse genes to ensure their correct regulatory control and usage, without perturbation of non-immunoglobulin gene function. We have demonstrated that Kymouse HK has a normal B-‐cell compartment, produces high antibody titres of all isotypes in response to antigen challenge and affinity matures antibodies in vivo, through normal rearrangement and somatic hypermutation processes."

Andrew Sandham, Chief Executive Officer, said: "We have developed the innovative Kymouse using novel embryonic stem cell and recombineering technologies. We have applied meticulous attention to quality control at every stage. I am delighted that our efforts have been validated through the launch of our first commercial strain. Our strategy is to use Kymouse HK for our own antibody drug discovery projects and to employ a broad partnering approach to make the strain available to pharmaceutical companies for their own discovery programmes."

About Kymab

Kymab is a "platform to product" biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.

Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics.

Founded in 2009, Kymab raised £20m of equity financing in 2010 from the investment division of the Wellcome Trust. It has an experienced management team with a successful track record in drug discovery and development.

For further information, please visit http://www.kymab.com

Contact Kymab:
Andrew Sandham, Chairman and Chief Executive Officer
Tel: +44(0)1223-833301, Email: andrew.sandham@kymab.com

M: Communications
Mary Clark
Tel: +44 207920 2361, Email: kymab@mcomgroup.com

Kymab, Kymouse, Kymouse HK are trademarks of Kymab Limited.



'/>"/>
SOURCE Kymab
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AMRI Announces Strategic Contract with Knopp Biosciences
2. Ceramic Society announces selection of Ichinose, Lawn and Moskowitz as 2012 Distinguish Life Members
3. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
4. Sequenom Announces Participation At Two Upcoming Investor Conferences
5. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
6. Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
7. Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia
8. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
9. Unprecedented Donation by Korean Stem Cell Leader: Dr. Jeong-Chan Ra of RNL Bio announces the donation of 90% of his wealth
10. Medical Marijuana, Inc. Portfolio Company PhytoSPHERE Systems Announces Successful Production of Hemp Harvesting for High Value CBD Oil
11. BIOCOM Announces Endorsement in 52nd Congressional District Race
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)...   MedyMatch Technology Ltd ., the data analytics healthcare ... support tools in the emergency room, announced today that it ... Technology Industries (IATI) BioMed Conference. The Conference ... National Life Sciences and Technology Week, and is being held ... Tel Aviv, Israel . Gene Saragnese ...
(Date:5/24/2016)... ... 2016 , ... Media Cybernetics, global image analysis leader, announces ... reflects a results-driven revitalization for a company with a renewed focus on innovation ... crisp, refreshed logo and a new web presence. , “I believe that the ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... That Will Drive Precision Farming in 2017 and Beyond. The paper outlines the ... in the precision ag industry. , “We’ve witnessed a lot of highs and ...
(Date:5/23/2016)... England , May 23, 2016 ... May 25 th at 10:15 a.m. ET before the ... the role genetically engineered mosquitos can play in controlling the ... carrier of the Zika virus.      (Logo: ... engineered male mosquito with a self-limiting gene. Trials in ...
Breaking Biology Technology:
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), a company ... of a new series of commercials on Time Warner Cable ... .  The commercials will air on Bloomberg TV, Fox Business ... show. --> NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ...
(Date:3/11/2016)... March 11, 2016 http://www.apimages.com ) - ... Picture is available at AP Images ( http://www.apimages.com ) - ... be used to produce the new refugee identity cards. DERMALOG will ... at CeBIT in Hanover next week.   ... will be used to produce the new refugee identity cards. DERMALOG ...
(Date:3/10/2016)... , March 10, 2016 ... new market research report "Identity and Access Management Market ... Audit, Compliance, and Governance), by Organization Size, by Deployment, ... 2020", published by MarketsandMarkets, The market is estimated to ... 12.78 Billion by 2020, at a Compound Annual Growth ...
Breaking Biology News(10 mins):